๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Effect of timing of postoperative chemotherapy on survival of dogs with osteosarcoma

โœ Scribed by John Berg; Mark C. Gebhardt; William M. Rand


Publisher
John Wiley and Sons
Year
1997
Tongue
English
Weight
99 KB
Volume
79
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

โœฆ Synopsis


rendering the micrometastases more susceptible to chemotherapy. Clinical trials Medicine, Tufts University, North Grafton, Massachusetts.

assessing the value of early postoperative initiation of chemotherapy for human breast carcinoma have yielded conflicting results. Osteosarcoma of dogs is a natu-


๐Ÿ“œ SIMILAR VOLUMES


Effect of fish oil, arginine, and doxoru
โœ Gregory K. Ogilvie; Martin J. Fettman; Craig H. Mallinckrodt; Judy A. Walton; Ro ๐Ÿ“‚ Article ๐Ÿ“… 2000 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 180 KB ๐Ÿ‘ 2 views

## BACKGROUND. Polyunsaturated n-3 fatty acids have been shown to inhibit the growth and metastasis of tumors. This double-blind, randomized study was designed to evaluate the hypothesis that polyunsaturated n-3 fatty acids can improve metabolic parameters, decrease chemical indices of inflammation

Effects of chemotherapy and remission on
โœ Gregory K. Ogilvie; David M. Vail; Stephen L Wheeler; Martin J. Fettman; Mowafak ๐Ÿ“‚ Article ๐Ÿ“… 1992 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 621 KB

After a 12-hour fast, blood samples were obtained from 27 dogs with previously untreated lymphoma before and 5, 15, 30, 45, and 60 minutes after an intravenous (IV) challenge with 500 mg/kg dextrose. This procedure was done for each dog before up to five treatments with the IV doxorubicin (30 mg/m2

Effect of adjuvant chemotherapy on time
โœ M. Steven Piver; Shashikant B. Lele; David L. Marchetti; Lawrence J. Emrich ๐Ÿ“‚ Article ๐Ÿ“… 1988 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 608 KB

We have evaluated the effect of adjuvant chemotherapy on time to recurrence and survival in two prospective trials of women with stage I uterine sarcomas. The first trial compared surgery only to surgery plus Adriamycin. The 5-year estimated survival rate was 36% for surgery alone and 63% for surger